{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Protagonist Therapeutics, Inc.
Is Protagonist Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Protagonist Therapeutics, Inc. is considered very expensive and overvalued due to high valuation ratios, including a P/E of 60 and an EV to EBITDA of 94.50, especially when compared to peers like Aurinia Pharmaceuticals, which has a P/E of 20.87.
Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics
Protagonist Therapeutics, Inc. has a notably high valuation compared to its peers, with a P/E ratio of 60 and elevated Price to Book and EV ratios. Despite this, the company has achieved strong performance metrics, including a significant year-to-date return and impressive growth over the past three years.
Is Protagonist Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Protagonist Therapeutics, Inc. is considered very expensive due to high valuation ratios, despite impressive returns of 100.78% year-to-date and 838.26% over three years, contrasting sharply with Aurinia Pharmaceuticals, Inc.'s fair valuation metrics.
Is Protagonist Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Protagonist Therapeutics, Inc. is considered very expensive due to high valuation ratios, including a P/E of 60 and an EV to EBITDA of 94.50, suggesting its impressive year-to-date returns may not be sustainable compared to more reasonably valued peers like Aurinia Pharmaceuticals, Inc.
Protagonist Therapeutics Hits Day High with 18% Surge Amid Market Decline
Protagonist Therapeutics, Inc. has seen notable stock activity, with significant gains over various time frames, including a 22.12% increase in the past week and an 81.62% rise over the past year. However, the company faces operational challenges, including a low return on equity and a sharp decline in operating profit.
Protagonist Therapeutics Opens with 27.21% Gain Amidst Market Decline
Protagonist Therapeutics, Inc. experienced a notable stock surge today, contrasting with broader market declines. Despite this positive movement, the company faces significant financial challenges, including low profitability and steep declines in operating profit and net sales. Technical indicators present a mixed outlook for the company's future.
Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Protagonist Therapeutics, Inc. has recently revised its evaluation amid current market conditions. The company's stock is priced at $64.14, reflecting a notable annual return of 44.56%, significantly outperforming the S&P 500. Technical indicators suggest mixed sentiments, highlighting the company's resilience and strong recovery over various time frames.
Is Protagonist Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Protagonist Therapeutics, Inc. has a mildly bullish technical trend, supported by bullish MACD and moving averages, despite some bearish signals from the RSI and KST, and has significantly outperformed the S&P 500 year-to-date and over the past year.
Is Protagonist Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Protagonist Therapeutics, Inc. shows a mildly bullish trend with positive weekly and monthly MACD indicators, but a bearish monthly RSI, while outperforming the S&P 500 with a year-to-date return of 67.95%.
Is Protagonist Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Protagonist Therapeutics, Inc. shows a mildly bullish trend with bullish MACD and moving averages, despite a bearish RSI, having outperformed the S&P 500 over various time frames but underperformed in the last week.
Protagonist Therapeutics Hits New 52-Week High of $68.26, Up 103%
Protagonist Therapeutics, Inc. achieved a new 52-week high of USD 68.26, reflecting strong performance in the pharmaceuticals sector. The company has grown 103.26% over the past year, with a market capitalization of USD 3,496 million, a P/E ratio of 60.00, and a return on equity of 7.79%.
Protagonist Therapeutics Hits New 52-Week High of $66.70, Up 98.82%
Protagonist Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial increase in its stock performance over the past year. With a market capitalization of USD 3,496 million, the company showcases strong financial metrics, including a notable price-to-earnings ratio and a solid balance sheet with no debt reliance.
Protagonist Therapeutics Hits New 52-Week High of $65.08
Protagonist Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial increase in its stock value over the past year. With a market capitalization of USD 3,496 million, the company exhibits strong growth potential, as indicated by its P/E ratio and return on equity, despite not offering dividends.
Protagonist Therapeutics Hits New 52-Week High of $64.59, Up 94.48%
Protagonist Therapeutics, Inc. achieved a new 52-week high of USD 64.59 on September 22, 2025, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company has seen a significant stock price increase over the past year, outperforming the S&P 500 and demonstrating effective management of shareholder equity.
Protagonist Therapeutics Hits New 52-Week High of $63.30
Protagonist Therapeutics, Inc. achieved a new 52-week high of USD 63.30 on September 19, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen an 87.52% growth over the past year, with notable financial metrics indicating effective management and a solid capital structure.
Is Protagonist Therapeutics, Inc. technically bullish or bearish?
As of September 12, 2025, Protagonist Therapeutics, Inc. has a mildly bullish technical trend, supported by strong short-term performance and mixed longer-term indicators, having outperformed the S&P 500 with a year-to-date return of 60.98%.
Is Protagonist Therapeutics, Inc. overvalued or undervalued?
As of July 7, 2025, Protagonist Therapeutics, Inc. is considered very expensive due to its high valuation ratios, including a P/E of 60 and an EV to EBITDA of 94.50, despite a strong year-to-date return of 60.98%, which suggests caution for potential investors.
Protagonist Therapeutics Hits New 52-Week High at $62.21
Protagonist Therapeutics, Inc. achieved a new 52-week high of USD 62.21 on September 18, 2025, marking a significant milestone for the small-cap company. Over the past year, it has seen an impressive stock price increase of 87.34%, outperforming the S&P 500, and demonstrating effective management with a return on equity of 7.79%.
Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Protagonist Therapeutics, Inc. has recently revised its evaluation amid current market dynamics. The company’s stock price is slightly down, but it has shown resilience with a 24.16% return over the past year, outperforming the S&P 500. Various technical indicators present mixed signals regarding momentum and price stability.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
